Show simple item record

dc.contributor.authorPlowe, Christopher V.en_US
dc.contributor.authorRoper, Callyen_US
dc.contributor.authorBarnwell, John W.en_US
dc.contributor.authorHappi, Christian T.en_US
dc.contributor.authorJoshi, Hema H.en_US
dc.contributor.authorMbacham, Wilfreden_US
dc.contributor.authorMeshnick, Steven R.en_US
dc.contributor.authorMugittu, Kefasen_US
dc.contributor.authorNaidoo, Inbaranien_US
dc.contributor.authorPrice, Ric N.en_US
dc.contributor.authorShafer, Robert W.en_US
dc.contributor.authorSibley, Carol Hopkinsen_US
dc.contributor.authorSutherland, Colin J.en_US
dc.contributor.authorZimmerman, Peter A.en_US
dc.contributor.authorRosenthal, Phillip J.en_US
dc.date.accessioned2010-05-06T20:06:04Z
dc.date.available2010-05-06T20:06:04Z
dc.date.issued2007en_US
dc.identifier.citationPlowe C, Roper C, Barnwell J, et al. World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal. 2007;6(1):121.en_US
dc.identifier.other10.1186/1475-2875-6-121en_US
dc.identifier.urihttp://www.malariajournal.com/content/6/1/121en_US
dc.identifier.urihttp://hdl.handle.net/1773/15844
dc.description.abstractMolecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs.en_US
dc.description.sponsorshipThe Bill and Melinda Gates Foundation.en_US
dc.language.isoen_USen_US
dc.titleWorld Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malariaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record